Talley N J, Locke G R, Lahr B D, Zinsmeister A R, Cohard-Radice M, D'Elia T V, Tack J, Earnest D L
Clinical Enteric Neuroscience, Translational and Epidemiological Research Program (CENTER), Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Aliment Pharmacol Ther. 2006 Apr 1;23(7):923-36. doi: 10.1111/j.1365-2036.2006.02845.x.
Trials in functional dyspepsia report placebo response rates of 30% to 40%.
We aimed to identify predictors of the placebo response.
Patients from primary, secondary and tertiary practices with functional dyspepsia defined by Rome II criteria were enrolled into one of four clinical trials; 220 patients were randomized to receive placebo. Scintigraphic assessment of gastric emptying at baseline was repeated at the end of the treatment in those with delayed emptying. After a 2 week run-in period, patients were followed for 8 weeks on placebo. Response was assessed on a weekly basis and a responder was defined as satisfactory relief of meal-related symptoms on at least 50% of weeks.
The mean age was 44 years (range 18-82) and 74% were female; 76 (35%) were placebo responders. The predominant symptom was an unstable measure over the trial. Independent predictors of a lower placebo response were lower body mass index and a more consistent predominant symptom pattern (both P < 0.05). No association was seen with age, gender, centre type, baseline symptom score, baseline or change in gastric emptying, or baseline quality of life.
In functional dyspepsia, a consistent predominant symptom pattern and lower body mass index may be associated with a lower placebo response rate.
功能性消化不良试验报告的安慰剂反应率为30%至40%。
我们旨在确定安慰剂反应的预测因素。
将来自初级、二级和三级医疗机构且符合罗马II标准定义的功能性消化不良患者纳入四项临床试验之一;220名患者被随机分配接受安慰剂治疗。对胃排空延迟的患者在治疗结束时重复进行基线时的胃排空闪烁扫描评估。在经过2周的导入期后,患者接受8周的安慰剂治疗随访。每周评估反应情况,反应者定义为在至少50%的周数内与进餐相关症状得到满意缓解。
平均年龄为44岁(范围18至82岁),74%为女性;76名(35%)为安慰剂反应者。在试验过程中,主要症状是一个不稳定的指标。安慰剂反应较低的独立预测因素是较低的体重指数和更一致的主要症状模式(均P<0.05)。未发现与年龄、性别、中心类型、基线症状评分、胃排空的基线或变化以及基线生活质量存在关联。
在功能性消化不良中,一致的主要症状模式和较低的体重指数可能与较低的安慰剂反应率相关。